Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
LAWRENCEVILLE, N.J., Nov. 07, 2017 -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. ET on Tuesday, November 14, 2017. To participate in the call, interested parties may dial 1-877-830-2649 (Toll-Free/North America) or 1-785-424-1824 (International/Toll) and ask for the Celsion Corporation 3rd Quarter 2017 Earnings Call (Conference Code: 3840213) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Tuesday, November 14, 2017 and will remain available until Tuesday, November 28, 2017. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 3840213. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. ET on Tuesday, November 14, 2017.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
[email protected]
